首页> 外文OA文献 >Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment

【2h】

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment

机译：磷酸化的p-70S6K预测绝经后乳腺癌患者中的他莫昔芬耐药性随机分配为他莫昔芬辅助治疗与不接受全身治疗之间

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Karin Beelen; Mark Opdam; Tesa M Severson; Rutger HT Koornstra; Andrew D Vincent; Jelle Wesseling; Jettie J Muris; Els MJJ Berns; Jan B Vermorken; Paul J van Diest; Sabine C Linn;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment [J] . Karin Beelen, Mark Opdam, Tesa M Severson, Breast Cancer Research . 2014,第1期

机译：磷酸化的P-70S6K预测佐剂Tamoxifen与全身治疗之间随机化的绝经后乳腺癌患者中的他莫昔芬抗性
2. CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment [J] . BeelenK., OpdamM., SeversonT.M., Breast cancer research and treatment. . 2013,第3期

机译：CYP2C19 * 2预测他莫昔芬在绝经后乳腺癌患者中的显着获益，该患者随机分为他莫昔芬辅助治疗和无系统治疗之间
3. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: austrian breast and colorectal cancer study group trial 6. [J] . Schmid M, Jakesz R, Samonigg H, Journal of Clinical Oncology . 2003,第6期

机译：他莫昔芬与他莫昔芬联合氨基谷氨酰胺作为激素受体阳性的绝经后乳腺癌患者辅助治疗的随机试验：奥地利乳腺癌和结直肠癌研究组试验6。
4. Study on the Efficacy Evaluation of Oral Sequential Tamoxifen in Postmenopausal Women with Hormone-dependent Breast Cancer [C] . Na Li, Yahua Sun, Sheng Zhao, International Conference on Life Sciences, Medicine, and Health . 2018

机译：激素依赖性乳腺癌后代妇女口腔序列儿毒素疗效评价研究
5. G Protein-coupled Estrogen Receptor 1 (GPER1) and Insulin-like Growth Factor Binding Protein 1 (IGFBP-1) Are Key Components of Tamoxifen Action and the Development of Tamoxifen Resistance in Breast Cancer Cells [D] . Zheng, Yan. 2019

机译：G蛋白偶联雌激素受体1（GPER1）和胰岛素样生长因子结合蛋白1（IGFBP-1）是他莫昔芬作用的关键组分和乳腺癌细胞中他莫昔芬抗性的发育
6. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment [O] . Karin Beelen, Mark Opdam, Tesa M Severson, 2014

机译：磷酸化的p-70S6K预测绝经后乳腺癌患者中的他莫昔芬耐药性随机分配为他莫昔芬辅助治疗与不接受全身治疗之间
7. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment [O] . Beelen, K. (Karin), Opdam, M. (Mark), Severson, T.M. (Tesa), 2014

机译：磷酸化的p-70S6K预测绝经后乳腺癌患者中的他莫昔芬耐药性随机分配为他莫昔芬辅助治疗与不接受全身治疗之间

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment

著录项

引文网络

相似文献

相关主题

期刊订阅